Skip Nav Destination
Issues
1 August 2018
-
Cover Image
Cover Image
The cover shows a section of CT-2A murine glioma cells 6 days post orthotopic implantation. Hematoxylin and eosin staining reveals a highly invasive tumor infiltrating the brain parenchyma. For details, see the article by Gedeon and colleagues on page 3611 of this issue. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
ISSN 1078-0432
EISSN 1557-3265
Highlights
CCR Translations
CCR Drug Updates
U.S. Food and Drug Administration Approval: Neratinib for the Extended Adjuvant Treatment of Early-Stage HER2-Positive Breast Cancer
Harpreet Singh; Amanda J. Walker; Laleh Amiri-Kordestani; Joyce Cheng; Shenghui Tang; Pamela Balcazar; Kimberly Barnett-Ringgold; Todd R. Palmby; Xianhua Cao; Nan Zheng; Qi Liu; Jingyu Yu; William F. Pierce; Selena R. Daniels; Rajeshwari Sridhara; Amna Ibrahim; Paul G. Kluetz; Gideon M. Blumenthal; Julia A. Beaver; Richard Pazdur
Review
Perspectives
Report from the SWOG Radiation Oncology Committee: Research Objectives Workshop 2017
Paul Okunieff; Katherine Casey-Sawicki; Natalie A. Lockney; Bradford S. Hoppe; Heiko Enderling; Chelsea Pinnix; James Welsh; Sunil Krishnan; Greg Yothers; Martin Brown; Susan Knox; Robert Bristow; Paul Spellman; Timur Mitin; Nima Nabavizadeh; Jerry Jaboin; H. Charles Manning; Felix Feng; Susan Galbraith; Abhishek A. Solanki; Matthew M. Harkenrider; Richard Tuli; Roy H. Decker; Steven E. Finkelstein; Charles C. Hsu; Chul S. Ha; Reshma Jagsi; Dean Shumway; Megan Daly; Tony J.C. Wang; Thomas J. Fitzgerald; Fran Laurie; David T. Marshall; David Raben; Louis Constine; Charles R. Thomas, Jr; Lisa A. Kachnic
Clinical Trials: Targeted Therapy
Author Choice
A First-in-Human Study of the New Oral Selective Estrogen Receptor Degrader AZD9496 for ER+/HER2− Advanced Breast Cancer
Erika P. Hamilton; Manish R. Patel; Anne C. Armstrong; Richard D. Baird; Komal Jhaveri; Matthias Hoch; Teresa Klinowska; Justin P.O. Lindemann; Shethah R. Morgan; Gaia Schiavon; Hazel M. Weir; Seock-Ah Im
Clinical Trials: Immunotherapy
A Multi-center Phase I Trial of Ipilimumab in Patients with Myelodysplastic Syndromes following Hypomethylating Agent Failure
Amer M. Zeidan; Hanna A. Knaus; Tara M. Robinson; Andrea M.H. Towlerton; Edus H. Warren; Joshua F. Zeidner; Amanda L. Blackford; Amy S. Duffield; David Rizzieri; Mark G. Frattini; Yair M. Levy; Mark A. Schroeder; Anna Ferguson; Katherine E. Sheldon; Amy E. DeZern; Ivana Gojo; Steven D. Gore; Howard Streicher; Leo Luznik; B. Douglas Smith
Precision Medicine and Imaging
Author Choice
The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients
Oliver A. Zill; Kimberly C. Banks; Stephen R. Fairclough; Stefanie A. Mortimer; James V. Vowles; Reza Mokhtari; David R. Gandara; Philip C. Mack; Justin I. Odegaard; Rebecca J. Nagy; Arthur M. Baca; Helmy Eltoukhy; Darya I. Chudova; Richard B. Lanman; AmirAli Talasaz
Author Choice
Validation of a Plasma-Based Comprehensive Cancer Genotyping Assay Utilizing Orthogonal Tissue- and Plasma-Based Methodologies
Justin I. Odegaard; John J. Vincent; Stefanie Mortimer; James V. Vowles; Bryan C. Ulrich; Kimberly C. Banks; Stephen R. Fairclough; Oliver A. Zill; Marcin Sikora; Reza Mokhtari; Diana Abdueva; Rebecca J. Nagy; Christine E. Lee; Lesli A. Kiedrowski; Cloud P. Paweletz; Helmy Eltoukhy; Richard B. Lanman; Darya I. Chudova; AmirAli Talasaz
Exome Sequencing of Plasma DNA Portrays the Mutation Landscape of Colorectal Cancer and Discovers Mutated VEGFR2 Receptors as Modulators of Antiangiogenic Therapies
Rodrigo A. Toledo; Elena Garralda; Maria Mitsi; Tirso Pons; Jorge Monsech; Estela Vega; Álvaro Otero; Maria I. Albarran; Natalia Baños; Yolanda Durán; Victoria Bonilla; Francesca Sarno; Marta Camacho-Artacho; Tania Sanchez-Perez; Sofia Perea; Rafael Álvarez; Alba De Martino; Daniel Lietha; Carmen Blanco-Aparicio; Antonio Cubillo; Orlando Domínguez; Jorge L. Martínez-Torrecuadrada; Manuel Hidalgo
Author Choice
A New Approach to Predict Progression-free Survival in Stage IV EGFR-mutant NSCLC Patients with EGFR-TKI Therapy
Jiangdian Song; Jingyun Shi; Di Dong; Mengjie Fang; Wenzhao Zhong; Kun Wang; Ning Wu; Yanqi Huang; Zhenyu Liu; Yue Cheng; Yuncui Gan; Yongzhao Zhou; Ping Zhou; Bojiang Chen; Changhong Liang; Zaiyi Liu; Weimin Li; Jie Tian
Author Choice
Clinicopathological Risk Factors for an Invasive Breast Cancer Recurrence after Ductal Carcinoma In Situ—A Nested Case–Control Study
Lindy L. Visser; Lotte E. Elshof; Michael Schaapveld; Koen van de Vijver; Emma J. Groen; Mathilde M. Almekinders; Carolien Bierman; Flora E. van Leeuwen; Emiel J. Rutgers; Marjanka K. Schmidt; Esther H. Lips; Jelle Wesseling
Paclitaxel Plasma Concentration after the First Infusion Predicts Treatment-Limiting Peripheral Neuropathy
Daniel L. Hertz; Kelley M. Kidwell; Kiran Vangipuram; Feng Li; Manjunath P. Pai; Monika Burness; Jennifer J. Griggs; Anne F. Schott; Catherine Van Poznak; Daniel F. Hayes; Ellen M. Lavoie Smith; N. Lynn Henry
Translational Cancer Mechanisms and Therapy
Author Choice
A Rationally Designed Fully Human EGFRvIII:CD3-Targeted Bispecific Antibody Redirects Human T Cells to Treat Patient-derived Intracerebral Malignant Glioma
Patrick C. Gedeon; Teilo H. Schaller; Satish K. Chitneni; Bryan D. Choi; Chien-Tsun Kuan; Carter M. Suryadevara; David J. Snyder; Robert J. Schmittling; Scott E. Szafranski; Xiuyu Cui; Patrick N. Healy; James E. Herndon, II; Roger E. McLendon; Stephen T. Keir; Gary E. Archer; Elizabeth A. Reap; Luis Sanchez-Perez; Darell D. Bigner; John H. Sampson
MEIS1 and MEIS2 Expression and Prostate Cancer Progression: A Role For HOXB13 Binding Partners in Metastatic Disease
Raj R. Bhanvadia; Calvin VanOpstall; Hannah Brechka; Nimrod S. Barashi; Marc Gillard; Erin M. McAuley; Juan Manuel Vasquez; Gladell Paner; Wen-Ching Chan; Jorge Andrade; Angelo M. De Marzo; Misop Han; Russell Z. Szmulewitz; Donald J. Vander Griend
Author Choice
Epigenome-wide SRC-1–Mediated Gene Silencing Represses Cellular Differentiation in Advanced Breast Cancer
Elspeth Ward; Damir Varešlija; Sara Charmsaz; Ailis Fagan; Alacoque L. Browne; Nicola Cosgrove; Sinéad Cocchiglia; Siobhan P. Purcell; Lance Hudson; Sudipto Das; Darran O'Connor; Philip J. O'Halloran; Andrew H. Sims; Arnold D. Hill; Leonie S. Young
Insulin-Like Growth Factor 2 mRNA-Binding Protein 3 is a Novel Post-Transcriptional Regulator of Ewing Sarcoma Malignancy
Caterina Mancarella; Michela Pasello; Selena Ventura; Andrea Grilli; Linda Calzolari; Lisa Toracchio; Pier-Luigi Lollini; Davide Maria Donati; Piero Picci; Stefano Ferrari; Katia Scotlandi
Nintedanib Is Active in Malignant Pleural Mesothelioma Cell Models and Inhibits Angiogenesis and Tumor Growth In Vivo
Viktoria Laszlo; Zsuzsanna Valko; Ildiko Kovacs; Judit Ozsvar; Mir Alireza Hoda; Thomas Klikovits; Dora Lakatos; Andras Czirok; Tamas Garay; Alexander Stiglbauer; Thomas H. Helbich; Marion Gröger; Jozsef Tovari; Walter Klepetko; Christine Pirker; Michael Grusch; Walter Berger; Frank Hilberg; Balazs Hegedus; Balazs Dome
Orthoxenografts of Testicular Germ Cell Tumors Demonstrate Genomic Changes Associated with Cisplatin Resistance and Identify PDMP as a Resensitizing Agent
Josep M. Piulats; August Vidal; Francisco J. García-Rodríguez; Clara Muñoz; Marga Nadal; Catia Moutinho; María Martínez-Iniesta; Josefina Mora; Agnés Figueras; Elisabet Guinó; Laura Padullés; Àlvaro Aytés; David G. Molleví; Sara Puertas; Carmen Martínez-Fernández; Wilmar Castillo; Merce Juliachs; Victor Moreno; Purificación Muñoz; Milica Stefanovic; Miguel A. Pujana; Enric Condom; Manel Esteller; Josep R. Germà; Gabriel Capella; Lourdes Farré; Albert Morales; Francesc Viñals; Xavier García-del-Muro; Julián Cerón; Alberto Villanueva
Corrections
Retraction
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds